According to this post in FierceHealthcare pharma companies have started adjusting pricing on their drugs to reflect its performance on improving patient outcomes. Merck has agreed to adjust pricing on Januvia and Janumet, which are diabetes drugs, based on how well they treat type 2 diabetes.
Performance-based pricing for meds is extremely rare, but with increased pressure coming from insurance companies it is only a matter of time before we will see more and more pharma companies following this pattern.
Read more about this piece on the NY Times
About Us
Health Care Insights - From Policy to Practice is the trusted source for news and commentary from the nation's leading Health Care Events such as Medicaid Drug Rebate Program Summit (MDRP), Medicaid Managed Care Congress (MMCC), FDA/CMS to inform Health Plans and Pharmaceutical Manufacturers on the latest developments on Medicare, Medicaid Managed Care, Government Programs, and Health Insurance Exchanges.
Topics we cover include reform, best business practices, the latest innovations, and novel payment models.
